Valorizing Agro‐Food Waste for Nutraceutical Development: Sustainable Approaches for Managing Metabolic Dysfunction‐Associated Steatotic Liver Disease and Related Co‐Morbidities DOI Creative Commons
Laura Comi, Claudia Giglione, Fationa Tolaj

et al.

Food Frontiers, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 25, 2024

ABSTRACT This comprehensive investigation delves into the interconnectedness of different features cardiometabolic syndrome, such as metabolic dysfunction‐associated steatotic liver disease (MASLD), atherosclerotic cardiovascular (ASCVD), and gut dysbiosis, highlighting crucial role nutraceuticals in their management prevention. Given significant overlap pathophysiology these conditions, treatment with nutraceuticals, especially those derived from agro‐food waste, offers a promising, sustainable, innovative approach to healthcare. The 2030 Agenda for Sustainable Development One Health concept are key frameworks selecting most interesting supply chain production ensuring environmental sustainability, agricultural practices. In this review, therapeutic potential kiwifruit apples has been explored, detailing how bioactive compounds, like polyphenols, fiber, pectin, kaempferol, phloretin, phlorizin, may contribute MASLD, ASCVD, dysbiosis. Various extraction methods active ingredients, including chemical, water, enzyme extractions, analyzed respective benefits drawbacks. By integrating scientific research, sustainable practices, methods, we can develop effective strategies combat pervasive health issues. holistic not only enhances individual outcomes but also supports broader societal goals, promoting healthier future all.

Language: Английский

Nutritional Strategies for Battling Obesity-Linked Liver Disease: the Role of Medical Nutritional Therapy in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Management DOI Creative Commons
Daniel Simancas‐Racines, Giuseppe Annunziata, Ludovica Verde

et al.

Current Obesity Reports, Journal Year: 2025, Volume and Issue: 14(1)

Published: Jan. 11, 2025

This narrative review explores the role of Medical Nutritional Therapy (MNT) in managing Metabolic-Associated Steatotic Liver Disease (MASLD), previously known as nonalcoholic fatty liver disease. It aims to examine effectiveness specific nutritional strategies preventing and treating this obesity-linked Emerging evidence underscores benefits Mediterranean diet, low-carbohydrate diets, intermittent fasting reducing fat, improving insulin sensitivity, mitigating inflammation. Supplementing with vitamin E, omega-3 acids, silymarin can potentially reduce fibrosis promote health. MNT is a key intervention for MASLD management, emphasizing dietary patterns, caloric restriction, nutraceutical supplementation. Integrating these lifestyle modifications, including regular physical activity, offers comprehensive approach metabolic outcomes patients MASLD. Further research needed refine personalize therapeutic interventions.

Language: Английский

Citations

8
Metformin and the Liver: Unlocking the Full Therapeutic Potential DOI Creative Commons
Federica Perazza, Laura Leoni, Santo Colosimo

et al.

Metabolites, Journal Year: 2024, Volume and Issue: 14(4), P. 186 - 186

Published: March 25, 2024

Metformin is a highly effective medication for managing type 2 diabetes mellitus. Recent studies have shown that it has significant therapeutic benefits in various organ systems, particularly the liver. Although effects of metformin on metabolic dysfunction-associated steatotic liver disease and steatohepatitis are still being debated, positive cirrhosis anti-tumoral properties, which can help prevent development hepatocellular carcinoma. Furthermore, been proven to improve insulin resistance dyslipidaemia, commonly associated with diseases. While more needed fully determine safety effectiveness use diseases, results promising. Indeed, terrific potential extending its full properties beyond traditional diabetes.

Language: Английский

Citations

10
A prospective study on the prevalence of at‐risk MASH in patients with type 2 diabetes mellitus in the United States DOI

Nikita Mittal,

Harris Siddiqi, Egbert Madamba

et al.

Alimentary Pharmacology & Therapeutics, Journal Year: 2024, Volume and Issue: 59(12), P. 1571 - 1578

Published: April 8, 2024

Summary Background There are limited data on the prevalence and treatment of at‐risk metabolic dysfunction‐associated steatohepatitis (MASH) among patients with type 2 diabetes (T2DM) in United States. Aim To estimate MASH a prospectively recruited cohort adults T2DM using new nomenclature endorsed by multiple societies. Methods This prospective study enrolled aged ≥50 from primary care endocrinology clinics southern California 2016 to 2023. Metabolic steatotic liver disease (MASLD) was defined an magnetic resonance imaging proton density fat fraction ≥5% at least one risk factor without any other chronic or secondary cause for hepatic steatosis. Results We included 530 adult T2DM. The mean (±SD) age body mass index (BMI) were 64.4 (±8.1) years 31.5 (±6.1) kg/m , respectively. Among T2DM, MASLD, cirrhosis 69.6%, 13.6% 6.8%, co‐existing obesity, 77.8%, 15.9% 9.0%, respectively, higher than participants obesity ( p < 0.0001, 0.0543 0.0128, respectively). Conclusion is high, posing significant liver‐related morbidity mortality. Approximately 14% may be candidates pharmacologic therapies specific MASH‐related fibrosis.

Language: Английский

Citations

9
New horizons in the diagnosis and management of patients with MASLD DOI Creative Commons
Karel J. van Erpecum, George Ν. Dalekos

European Journal of Internal Medicine, Journal Year: 2024, Volume and Issue: 122, P. 1 - 2

Published: Feb. 12, 2024

The collection 'New horizons in the diagnosis and management of patients with metabolic dysfunction-associated steatotic liver disease (MASLD)' that is presented here, deals natural history, non-invasive tests risk stratification, associated cardiovascular risk, treatment options MASLD including pharmacological for this disease. In recent years, (SLD) -previously known as fatty disease- has replaced viral hepatitis most common worldwide due to spread Western diet increasing prevalence obesity well introduction highly effective antiviral therapy.

Language: Английский

Citations

6
Exploring Varied Treatment Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) DOI Creative Commons

Amani Elshaer,

David M. Chascsa, Blanca Lizaola‐Mayo

et al.

Life, Journal Year: 2024, Volume and Issue: 14(7), P. 844 - 844

Published: July 3, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD) represents a disorder characterized by steatosis with underlying metabolic risk factors. The prevalence of MASLD continues to rise, leading increased patient various complications. Recent research has been focused on new therapeutic strategies reduce the incidence and provide effective treatment plans prevent further irreversible damage. approach is multifactorial, primary focus weight loss management comorbidities through lifestyle modifications, pharmacotherapy, or surgical options. Ongoing exploring pharmacological therapies that could enhance MASLD.

Language: Английский

Citations

6
An updated overview on hepatocellular carcinoma in patients with Metabolic dysfunction-Associated Steatotic Liver Disease: Trends, pathophysiology and risk-based surveillance DOI Creative Commons
Angelo Armandi, Chiara Rosso, Gian Paolo Caviglia

et al.

Metabolism, Journal Year: 2024, Volume and Issue: unknown, P. 156080 - 156080

Published: Nov. 1, 2024

Language: Английский

Citations

6
Advancing precision medicine in metabolic dysfunction-associated steatotic liver disease DOI
Bryan Adrián Priego-Parra, Rocío Gallego‐Durán, Berenice M Román-Calleja

et al.

Trends in Endocrinology and Metabolism, Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

Language: Английский

Citations

0
Implementation of a WeChat mini-program-driven lifestyle intervention among overweight or obese individuals with metabolic dysfunction-associated fatty liver disease (Preprint) DOI
C. N. Sun, Guangyu Chen,

Cuicui Shi

et al.

Published: April 18, 2025

BACKGROUND Weight loss is the standard recommendation for patients with metabolic dysfunction-associated fatty liver disease (MAFLD), but its successful implementation difficult in practice. Digital lifestyle interventions may provide an efficient and scalable solution to enhance patient self-management. OBJECTIVE This study aimed assess effects of a WeChat mini-program-delivered intervention on weight hepatic steatosis among overweight or obese individuals MAFLD METHODS Overweight adults clinically diagnosed transient elastography examination were enrolled this prospective randomized controlled trial. Patients randomly assigned receive either mini-program management (intervention group) care (control at 1:1 ratio. Body clinical parameters assessed baseline then 6 months. RESULTS Among 89 included patients, 60.0% achieved ≥5% loss, 24.4% had ≥10% group, which greater than those control group (P <0.05). Importantly, receiving significantly more likely achieve attenuation parameter （CAP）reduction CAP normalization (57.8% vs. 31.8%, P In parallel, presented reductions enzymes (ALT, AST, GGT) (fasting insulin, HbA1c, TG, HDL-C) According fibrosis assessment, only FibroScan-aspartate aminotransferase (FAST) score decreased No significant difference was found stiffness measurement (LSM) values noninvasive scores (APRI, FIB-4, NFS, Agile 3+) between groups (P>0.05). CONCLUSIONS coaching via demonstrates efficacy enhancing reduction, improving steatosis, ameliorating disorders, offering novel perspectives regarding practicality therapeutic value digital tools managing through behavioral interventions. CLINICALTRIAL Chinese Clinical Trial Registry ChiCTR2500100197; https://www.chictr.org.cn/

Language: Английский

Citations

0
Expanding the Use of SGLT2 Inhibitors in T2D Patients Across Clinical Settings DOI Creative Commons
Alessandro Cuttone, Vittorio Cannavò, Rana Abdullah

et al.

Cells, Journal Year: 2025, Volume and Issue: 14(9), P. 668 - 668

Published: May 2, 2025

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are currently recommended in patients with type 2 diabetes (T2D) to reduce serum glucose levels. Moreover, robust evidence has clearly demonstrated their beneficial cardiovascular and renal effects, making this class of drugs pivotal for the treatment T2D, especially when complicated by diabetic kidney disease or heart failure. However, several other comorbidities frequently encountered T2D beyond these long-term complications, internal medicine setting. For some comorbidities, such as MAFLD cognitive impairment, association is increasingly recognized, hypothesis a common pathophysiologic background, whereas, others, coincident epidemiology linked ageing populations, including that subjects, may be advocated. In effort personalizing treatment, on potential effects SGLT2i different clinical conditions accumulating. The purpose narrative review update current literature settings glycaemic control, elucidate molecular mechanisms which they exert effects.

Language: Английский

Citations

0
Non-Alcoholic Fatty Liver Disease in Everyday Clinical Practice: From Diagnosis to Therapy DOI Creative Commons
Marcin Kosmalski, Łukasz Mokros

Life, Journal Year: 2025, Volume and Issue: 15(3), P. 363 - 363

Published: Feb. 25, 2025

Non-alcoholic fatty liver disease (NAFLD) is currently one of the most common hepatic disorders observed in daily medical practice [...]

Language: Английский

Citations

0